BIIB vs SYRE · P/E 21, rev $9.89B vs $7.60B cap
Biogen Inc (BIIB) versus Spyre Therapeutics Inc. (SYRE) — a side-by-side from cached financials, not a winner call.
Biogen Inc (BIIB) is a drug manufacturers - general company listed on NASDAQ. It is led by Christopher A. Viehbacher.
Spyre Therapeutics Inc. (SYRE) is a biotechnology company listed on NASDAQ.
Latest reported BIIB revenue for 2025-12-31 was $9.89B. Net income was $1.29B. Revenue was up 2.2% from 2024-12-31 to 2025-12-31. BIIB currently screens at market cap $29.33B and trailing P/E 21.4.
Latest reported SYRE revenue for 2025-12-31 was $0. Net income was -$155.2M. SYRE currently screens at market cap $7.60B.
BIIB currently screens at market cap $29.33B and trailing P/E 21.4. SYRE currently screens at market cap $7.60B.
Not investment advice. Open the BIIB and SYRE stock pages for the full models.
Not investment advice.